Literature DB >> 10982678

Role of autologous blood transfusion in sacral tumor resection: patient selection and recovery after surgery and blood donation.

S Nakai1, H Yoshizawa, S Kobayashi, K Naga, H Ichinose.   

Abstract

We carried out sacral en-bloc resection in six patients (three with chordoma; one with pheochromocytoma; one with malignant schwannoma; and one with giant cell tumor) using preoperatively collected autologous blood, to avoid homologous blood transfusion. An average of 3200 ml was collected preoperatively, with patients receiving recombinant human erythropoietin (r-HuEPO), at a total dose of 130 000 units on average. In four patients, we were able to accomplish the surgery without homologous blood transfusion. Postoperatively, the hemoglobin level in these four patients recovered to the pre-collective level in 4.5 weeks, on average. These clinical results indicate that en-bloc sacrectomy, which requires a large volume of blood transfusion, can be accomplished with preoperatively collected autologous blood alone.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10982678     DOI: 10.1007/s007760070037

Source DB:  PubMed          Journal:  J Orthop Sci        ISSN: 0949-2658            Impact factor:   1.601


  3 in total

1.  Risk factors for blood loss during sacral tumor resection.

Authors:  Xiaodong Tang; Wei Guo; Rongli Yang; Shun Tang; Tao Ji
Journal:  Clin Orthop Relat Res       Date:  2008-09-10       Impact factor: 4.176

2.  Sacral Nerves Reconstruction After Surgical Resection of a Large Sacral Chordoma Restores the Urinary and Sexual Function and the Anal Continence.

Authors:  Luigi Valentino Berra; Daniele Armocida; Mauro Palmieri; Valerio Di Norcia; Luca D'Angelo; Massimo Mongardini; Massimo Vigliotta; Edoardo Maccari; Antonio Santoro
Journal:  Neurospine       Date:  2022-01-30

3.  Pre-operative embolization facilitating a posterior approach for the surgical resection of giant sacral neurogenic tumors.

Authors:  Kangwu Chen; Ming Zhou; Huilin Yang; Zhonglai Qian; Genlin Wang; Guizhong Wu; Xiaoyu Zhu; Zhiyong Sun
Journal:  Oncol Lett       Date:  2013-05-08       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.